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incidence and epidemiology
Mantle cell lymphoma (MCL) is a less frequent subtype of
lymphoid malignancies and represents 6%–9% of malignant
lymphoma in Western Europe. The annual incidence of this
disease has increased during recent decades to 1–2/100 000 re-
cently. MCL is more common in males than in women with a
3 : 1 ratio.
diagnosis and pathology/molecular
biology
Diagnosis should be based on a surgical specimen, preferably a
lymph node biopsy. Core biopsies should only be carried out in
patients without easily accessible lymph nodes (e.g. retroperi-
toneal bulk), keeping in mind the heterogeneity of MCL. In the
rare cases with leukaemic manifestation only, a bone marrow
biopsy may be sufficient if additional diagnostic measures are
applied [immunohistochemistry, detection of t(11;14)(q13;
q32)]. Fine-needle aspirations are inappropriate for a reliable
evaluation of additional risk factors (cytology, cell proliferation).
The histological report should give the diagnosis according to
the World Health Organization (WHO) classification and Ki-67
as the most established histomorphological risk factor [1] [I, A].
Most tumours have a classic morphology of small-medium sized
cells with irregular nuclei. However, the malignant lymphocytes
may present with a spectrum of morphological variants, includ-
ing small round (resembling chronic lymphocytic leukaemia),
marginal zone-like, pleomorphic and blastoid cells. As only
the minority of these cases are correctly diagnosed based on classi-
cal histology only, review by an expert haematopathologist is
advised. Specifically, additional immunohistochemistry for
detection of the pathognomonic cyclin D1 overexpression is
mandatory.
In the rare cyclin D1-negative cases, detection of Sox-11 may
help to establish the diagnosis [2].
Extended gene expression profiling suggests a more favour-
able clinical course in cases with low cell proliferation; however,
this technique is not yet applicable in clinical routine practice. If
possible, additional biopsy material should be stored freshly
frozen to allow additional molecular (currently still investiga-
tional) analyses.
staging and risk assessment
Since treatment may differ depending on the stage of the
disease, initial staging should be thorough, particularly in the
rare cases with non-bulky stages I and II (Table 1). Initial work-
up should include a computed tomography (CT) scan of the
neck, thorax, abdomen and pelvis, and a bone marrow aspirate
and biopsy (Table 2). Positron emission tomography-CT (PET-
CT) scan is not mandatory, but may be recommended and is es-
pecially useful in the rare limited stages I/II, before localised
radiotherapy [IV, C]. Gastrointestinal endoscopy is also recom-
mended in these rare cases to detect asymptomatic involvement.
Of note, when analysed, the majority of MCL patients will have
gastrointestinal involvement.
Central nervous system involvement is rare in asymptomatic
patients at diagnosis, but a lumbar puncture may be considered
in high-risk cases [at least two of the following risk factors: blas-
toid variant, elevated lactate dehydrogenase (LDH), impaired
performance status] or neurological symptoms [3].
A full blood count, blood chemistry including LDH and uric
acid as well as screening tests for human immunodeficiency virus
(HIV) and hepatitis B and C are required. Staging is carried out
according to the Ann Arbor classification system (Table 1), with
mention of bulky disease >5 cm when appropriate.†Approved by the ESMO Guidelines Working Group: August 2014.
*Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L.
Taddei 4, CH-6962 Viganello-Lugano, Switzerland.
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For prognostic purposes, a ‘Mantle cell lymphoma
International Prognostic Index’ (Table 3; web-based calculator:
www.european-mcl.net/de/clinical_mipi.php) has been estab-
lished [I, A] [4].
The evaluation of the Ki-67 proliferative antigen is the most
applicable method to evaluate cell proliferation, and is consid-
ered the most established biological risk factor in MCL. As the
reproducibility of quantitative scores among pathologists may
vary, a standardised method has been suggested [5].
indolent subtype of MCL
Most patients with MCL follow an aggressive clinical course.
However, a subset of patients may exhibit a more indolent evo-
lution. These cases are commonly characterised by a non-nodal
leukaemic presentation with only bone marrow involvement,
and splenomegaly [6]. In addition, cases with low Ki-67 (≤10%)
tend to have a more indolent course. SOX-11 negativity may
also identify cases with more indolent clinical behaviour.
However, its role is controversial and additional p53 mutations
may cause an aggressive clinical evolution [7] (Figure 1).
Unfortunately, there are no markers to definitely predict in-
dolent behaviour, but a short watch-and-wait period under
close observation seems to be appropriate in suspected indolent
cases with low tumour burden [III, B] [9].
treatment
first line
stage I–II. In the small proportion of patients with limited non-
bulky stages I–II, radiotherapy (involved field, 30–36 Gy) has
been suggested to achieve long-term remissions [10]. In contrast,
in a randomised study, all patients with early-stage MCL relapsed
within 1 year [11]. Thus, a shortened conventional chemotherapy
induction followed by consolidating radiation (similar to diffuse
large-cell lymphoma) may be most appropriate in these cases
[IV, B].
In stage I–II patients with large tumour burden or adverse prog-
nostic features, systemic therapy as indicated for advanced stages
would be appropriate in most cases; a radiation consolidation
may be considered, depending on tumour location and anticipated
side-effects [IV, B].
Table 2. Diagnostic work-up
History B symptoms
Physical
examination
Waldeyer’s ring, peripheral lymph nodes, liver,
spleen
Laboratory
work-up
Blood and differential count in leukaemic cases:
FACS (CD5/CD20+, CD23/CD200), FISH for
t(11;14) recommended
LDH, uric acid, liver and renal function
electrophoresis (optional: immune fixation)
Serology Hepatitis B, C and HIV serology
Imaging Chest X-ray
Abdominal ultrasound
CT neck, chest, abdomen, pelvis
MRT only in selected locations (CNS)
Optional: PET
Bone marrow Histology (cyclin D1 immunohistochemistry)
Cytology
Recommended: FACS, FISH for t(11;14)
Optional: PCR for IgH rearrangement
Toxicity Electrocardiogram, cardiac ultrasound (before
anthracyclines, ASCT)
Pulmonary function (before ASCT)
Creatinine clearance
Optional: reproductive counselling in young
patients
FACS, fluorescence-activated cell sorting; FISH, fluorescence
in situ hybridisation; LDH, lactate dehydrogenase; HIV, human
immunodeficiency virus; CT, computed tomography; MRT,
magnetic resonance tomography; CNS, central nervous system; PET,
positron emission tomography; PCR, polymerase chain reaction;
ASCT, autologous stem-cell transplantation.
Table 3. Simplified MIPI risk factor
Points Age (years) ECOG LDH (ULN) WBC (109/l)
0 <50 0–1 <0.67 <6.700
1 50–59 – 0.67–0.99 6700–9.999
2 60–69 2–4 1.00–1.49 10.000–14.999
3 >70 – ≥1.50 ≥15.000
For each prognostic factor, 0–3 points were given to each patient
and points were summed up to a maximum of 11. Patients with 0–3
points in summary were classified as low risk, patients with 4–5
points as intermediate risk and patients with 6–11 points as high
risk. ECOG performance status was weighted with 2 points if
patients were unable to work or bedridden (ECOG 2–4). LDH was
weighted according to the ratio to the ULN. Thus, for an ULN of
240 U/l, the limits were 180, 240 and 360 U/l.
MIPI, mantle cell lymphoma international prognostic index; ECOG,
Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase;
ULN: upper limit of normal range; WBC: white blood count.
Table 1. Ann Arbor classification
Stage Area of involvement
I (IE) One lymph node region or extralymphatic site (IE)
II (IIE) Two or more lymph node regions or at least one
lymph node region plus a single localised
extralymphatic site(IIE) on the same side of the
diaphragm
III (IIIE, IIIS) Lymph node regions or lymphoid structures (e.g.
thymus, Waldeyer’s ring) on both sides of the
diaphragm with optional localised extranodal site
(IIIE) or spleen (IIIS)
IV Diffuse or disseminated extralymphatic organ
involvement
A, no symptoms; B, unexplained fever of >38°C, drenching night
sweats; or loss of >10% body weight within 6 months.
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stage III–IV
induction: In all symptomatic patients and asymptomatic cases
with high tumour burden, therapy should be initiated at diagnosis
[I, A]. The current therapeutic approach is based on clinical risk
factors, symptoms and patient characteristics (Figure 2).
elderly patients: Based on a median age of 65 years at first
diagnosis, the majority of patients do not qualify for dose-
intensified regimens. Three prospective first-line trials, a salvage
trial and a systematic meta-analysis support an improved
overall response, progression-free survival (PFS) and overall
survival (OS) if rituximab was added to chemotherapy (Table 4)
[I, A] [12].
Rituximab in combination with chemotherapy such as CHOP
(cyclophosphamide, doxorubicin, vincristine and prednisone)
or bendamustine should be used [I, B] [13, 18]. R-CVP
Germline
RB1 p27
Naive B cell
„indolent“ MCL (15%) „classical“ MCL (80%) „transformed“ MCL (5%)
t(11;14)
Cyclin D1
Early MCL
ATM
CHK2
Complex
karyotypes
High
proliferation
INK4A/CDK4/RBI
ARF/MDM2/p53
Classical MCL Blastoid MCL
ATM
CHK2
Figure 1. Molecular pathogenesis of mantle cell lymphoma. Reprinted from [8]. Reused with permission. Copyright 2014 American Society of Clinical
Oncology. All rights reserved.
Young patient (65) Elderly patient (>65)
First line treatment
Compromised patient
Conventional
Immuno-chemotherapy
(e.g. R-CHOP, BR)
Rituximab maintenance
radioimmunotherapy
Watch and wait ?
R-Chlorambucil
BR
1. Relapse
High tumour load:
Immuno-chemotherapy
(e.g. BR, R-DHAP)
Allo-transplant
Radioimmunotherapy
Rituximab maintenance
Immuno-chemotherapy
(e.g. BR, R-FC)
Targeted approaches
ASCT
Radioimmunotherapy
Rituximab maintenance
Immuno-chemotherapy
(e.g. BR)
Targeted approaches
Higher relapse
Targeted approaches: Temsirolimus, Bortezomib*, Ibrutinib, Lenalidomide*
(preferable in combination)
Repeat previous therapy (long remissions)
R, rituximab; CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; B, bendamustine;
FC, fludarabine/cyclophosphamide; ASCT, autologous stem-cell transplantation; *currently not registered in
this indication in the European Union (EU).
Dose-intensified
Immuno-chemotherapy
(R-CHOP + R-high dose Ara-C
(alternating or sequential)
=>ASCT)
Figure 2. Therapeutic recommendations. Modified from [8]. Reused with permission. Copyright 2014 American Society of Clinical Oncology. All rights
reserved.
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(cyclophosphamide, vincristine and prednisone) combination
results in inferior response rates and PFS [19]. Purine analogue-
based schemes [R-FC (fludarabine and cyclophosphamide)
or R-FM (fludarabine and mitoxantrone)] are also discouraged
due to early failures and long-lasting myelosuppression [17]
[I, D].
In frail patients, a less intense immunochemotherapy [chlor-
ambucil, VADC (vincristine, doxorubicin, oral dexamethasone,
chlorambucil) or PEP-C (prednisone, etoposide, procarbazine,
cyclophosphamide)] may be considered, aiming primarily at
palliation [II, B]. However, targeted therapy exhibiting a low
toxicity profile may be used in this population.
Antibody monotherapy [rituximab, radioimmunotherapy
(RIT)] achieves only moderate response rates and is therefore
not recommended [III, B] [20].
In patients with positive hepatitis B serology, prophylactic
antiviral medication is strongly recommended [I, A] [21].
consolidation/maintenance: Rituximab maintenance signifi-
cantly improves PFS and even OS after R-CHOP (rituximab, cyclo-
phosphamide, doxorubicin, vincristine, prednisolone) (75% versus
58% after 3 years, P < 0.0001) [I, A] [17].
RIT consolidation also prolongs PFS after chemotherapy, but
its benefit seems to be inferior in comparison to rituximab
maintenance [II, B] [22].
younger patients: Although no curative treatment is available
for MCL so far, an intensive approach, e.g. by ASCT, has been
demonstrated to induce higher response and survival rates in fit
patients, independent of the addition of rituximab [I, B] [23, 24]
(Table 5).
In addition, a randomised trial confirmed that a cytarabine-
containing induction achieves a significantly improved median
time to treatment failure (P = 0.038) and a trend for median OS
(P = 0.045) [I, B] [25]. In contrast, an induction based on high-
dose cytarabine alone achieves only insufficient response rates
[III, D] [34]. Therefore, a rituximab containing induction of
CHOP and high dose Ara-C followed by high dose consolida-
tion and ASCT is recommended.
In a retrospective study comparison of the Nordic, HOVON
and MCL younger protocols, total body irradiation (TBI) before
ASCT was confirmed to be beneficial only in partial response
(PR) patients [II, B] [35]. In contrast, the benefit of RIT has not
been demonstrated in inter-study comparisons.
An upfront, dose-intensified approach (R-Hyper-CVAD, rituxi-
mab in combination with fractionated cyclophosphamide, vincris-
tine, anthracycline and dexamethasone) with alternating high-dose
methotrexate/cytarabine cycles also achieved very high response
and survival rates in phase II studies, but its feasibility is hampered
by a significant therapy-associated toxicity [II, C] [31–33].
The role of rituximab and lenalidomide maintenance after au-
tologous transplantation is currently being investigated by the
randomised LyMa [36] and MCL 0208 trials, respectively.
So far, there are no data to support the application of allogen-
eic transplantation as part of front-line treatment [II, D] [37].
relapsed disease
A repeated biopsy is strongly recommended to identify prognos-
tically important features of MCL.
Selection of salvage treatment depends on efficacy of prior regi-
mens. In early relapses (<12–24 months), a non-cross-resistant
scheme should be preferred (bendamustine or high-dose-Ara-C
Table 4. Published clinical studies investigating first-line conventional immunochemotherapy in mantle cell lymphoma
Author Study features Evaluable
patients
Therapeutic regimen ORR%
(CR%)
Median PFS
(months)
2-years OS
Conventional immunochemotherapy
Lenz et al. [13] Phase III,
randomised
112 CHOP versus R-CHOP 75 (7) versus
94 (34)
21 versus 14 (TTF) 76% versus 76%
Herold et al. [14] Phase III,
randomised
90 MCP versus R-MCP 63 (15) versus
71 (32)
18 versus 20 52% versus 55%
(4-year OS)
Gressin et al. [15] Phase II 113 Rituximab–VADC 73 (46) 16 (no ASCT)
58 (ASCT)a
62% (3-year OS)a
Sachanas et al. [16] Phase II 20 Rituximab–chlorambucil 95 (90) 89% (3-year PFS) 95% (3-year OS)
Kluin-Nelemans
et al. [17]
Phase III,
randomised
485 Induction: R-CHOP
versus R-FC
86 (34) versus
78 (40)
28 versus 28 (TTF) 62% versus 47%
(4-year OS)
Maintenance: rituximab
versus interferon alpha
– 58% versus 29%
(4-year DOR)
79% versus 67%
(4-year OS)
Rummel et al. [18] Phase III,
randomised
514 (94 MCL) R-CHOP versus rituximab–
bendamustine
91 (30) versus
93 (40)
21 versus 35 No differences
Data derived from the overall population of the study, not exclusively from patients with MCL.
aForty-nine patients received ASCT consolidation.
R, rituximab; B, bendamustine; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; FC, fludarabine, cyclophosphamide;
MCP, mitoxantrone, procarbazine, lomustine; ASCT, autologous stem-cell transplantation; VADC, vincristine, doxorubicin, oral dexamethasone,
chlorambucil; TTF, time to failure; DOR, duration of response; ORR, overall response rate; CR, complete response.
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Table 5. Published clinical studies investigating first-line dose-intensified therapy in mantle cell lymphoma
Author Study features Evaluable
patients
Therapeutic regimen ORR% (CR%) Median PFS (years) Median OS
(years)
Dropout
rate
TRM Secondary
tumours
rate
ASCT-based regimens
Dreyling
et al. [23]
Phase III, randomised 122 R-CHOP + TBI + ASCT versus
R-CHOP + TBI + interferon-α
98 (81) versus 99 (37) 3.3 versus 1.4 NR (83% 3-year
OS) versus
NR (77% 3-year
OS)
13% versus
N/A
5% versus
0%
5%
Hermine
et al. [25]
Phase III, randomised 455 R-CHOP + TBI + ASCT versus
R-CHOP/R-DHAP +HD-
araC + ASCT
98 (63) versus 99 (61) 3.8 versus 7.3 6.8 versus NR N/A 4% N/A
Damon
et al. [26]
Phase II 77 R-CHOP +methotrexate + HD-araC/
etoposide + ASCT
88 (69) NR (56% 5-year PFS) NR (64% 5-year
OS)
13% 3% N/A
Van’t Veer
et al. [27]
Phase II 87 R-CHOP +HD-araC + ASCT 70 (64) NR (36% 4-year PFS) NR (66% 4-year
OS)
30% 5% N/A
Geisler et al.
[28]
Phase II 160 R-Maxi-CHOP +HD-araC + ASCT 96 (54) 7.4 NR (64% 10-year
OS)
9% 5% 4%
Delarue
et al. [29]
Phase II 60 R-CHOP/R-DHAP +HD-
araC + ASCT
100 (96) 6.9 NR (75% 5-year
OS)
18% 1.5% 18%
Touzeau
et al. [30]
Retrospective 396 Different ASCT-based schedules 83 (77) NR (67% 3-year PFS) NR (83% 3-year
OS)
N/A 2.5% 6%
Non-ASCT-based regimens
Romaguera
et al. [31]
Phase II, monocentric 97 R-Hyper-CVAD 97 (87) 4.6 NR (64% 10-year
OS)
29% 8% 5%
Merli et al.
[32]
Phase II, multicentric 60 R-Hyper-CVAD 83 (72) NR (73% 5-year PFS) NR (61% 5-year
OS)
63% 6.5% 1.5%
Bernstein
et al. [33]
Phase II, multicentric 49 R-Hyper-CVAD 86 (55) 4.8 6.8 39% 2% 4%
R, rituximab; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; DHAP, dexamethasone, HD-araC, high dose Ara-C (cytarabine), Hyper-CVAD, hyperfractionated cyclophosphamide,
vincristine, anthracycline, dexamethasone; TBI, total body irradiation; ASCT, autologous stem-cell transplantation; NR, not reached; TRM, treatment-related mortality.
Volum
e
25
|S
upplem
ent3
|S
eptem
ber2014
doi:10.1093/annonc/m
du264
|
iii
A
nnals
ofO
ncology
clinicalpractice
guidelines
 by guest on October 26, 2016 http://annonc.oxfordjournals.org/ Downloaded from 
containing regimens, e.g. R-BAC after CHOP or vice versa) [38].
Rituximab should be added if the previous antibody-containing
scheme achieved >6–12 months duration of remission [IV, B].
In cases of early relapses or in refractory cases, newer tar-
geted approaches should be strongly considered (Figure 2).
Currently, temsirolimus is the only compound registered for
relapsed MCL in the EU based on a randomised trial [39].
Among the compounds registered in the United States (borte-
zomib, ibrutinib and lenalidomide), ibrutinib achieves
the highest response rates but longer follow-up is warranted
[40–42] (Table 6).
Targeted approaches in combination with immunochem-
otherapy have been suggested but are still investigational.
Rituximab maintenance has a favourable safety profile and
prolongs PFS and OS in relapsed disease [I, A] [59]. However,
such a second-line maintenance treatment has not been investi-
gated in patients relapsing after front-line maintenance [IV, D].
RIT consolidation seems to result in extended remission dura-
tions [55], especially in elderly patients with comorbidities not
eligible for dose intensification [IV, B].
High-dose chemotherapy with ASCT may be considered in
patients relapsed after conventional first-line therapy. However,
Table 6. Published clinical studies investigating molecular targeted approaches in relapsed mantle cell lymphoma
Author Study features Evaluable
patients
Therapeutic regimen ORR% (CR
%)
Median PFS
(months)
Median OS
(months)
Proteasome inhibitors
Goy et al. [40] Phase II 141 Bortezomib 33 (8) 6.7 (TTP) 23.5
Lamm et al. [43] Phase II 16 Bortezomib, rituximab, dexamethasone 81 (44) 12.1 38.6
Kouroukis et al. [44] Phase II 25 Bortezomib, gemcitabine 60 (11) 11.4 N/A
mTOR inhibitors
Witzig et al. [45] Phase II 34 Temsirolimus 38 (3) 6.5 (TTP) 12
Ansell et al. [46] Phase II 27 Temsirolimus 41 (4) 6 (TTP) 14
Hess et al. [39] Phase III,
randomised
54 Temsirolimus 175 mg/75 mg 22 (2) 4.8 12.8
54 Temsirolimus 175 mg/25 mg 6 (0) 3.4 10
53 Investigator’s choice 2 (2) 1.9 9.7
Ansell et al. [47] Phase II 69 Temsirolimus, rituximab 59 (19) 9.7 29.5
Renner et al. [48] Phase II 35 Everolimus 20 (6) 5.5 N/A
Immunomodulatory drugs
Zinzani et al. [41] Phase II 57 Lenalidomide 35 (12) 8.8 NR
Goy et al. [49] Phase II 134 Lenalidomide 28 (8) 4 19
Wang et al. [50] Phase II 44 Lenalidomide, rituximab 57 (36) 11.1 24.3
Zaja et al. [51] Phase II 33 Lenalidomide, dexamethasone 52 (24) 12 20
Harel et al. [52] Retrospective 58 Thalidomide ± bortezomib ± rituximab 50 (21) NR (1-year
TTF 29%)
NR (62% 1-
year OS)
Ruan et al. [53] Phase II 22 Metronomic prednisone, etoposide
Procarbazine, cyclophosphamide,
rituximab, thalidomide
73 (32) 10 NR (45% 2-
year OS)
Antibody-based approaches
Wang et al. [54] Phase II 32 90Y-ibritumumab tiuxetan 31 (16) 6 (EFS) 21
Ferrero et al. [55] Phase II 15b+ 90Y-ibritumumab tiuxetan 40 (20) 3.7 13.8
30b 72 (38) 8.9 32.2
Morschhauser et al. [56] Phase II 40 (15
MCL)
GA-101 27 (13) 2.7a N/A
BCR signalling inhibitors
Wang et al. [42] Phase II 111 Ibrutinib 68 (21) 13.9 NR (58%
1.5-year
OS)
Kahl et al. [57] Phase I 16 Cal-101 62 (N/A) 3 (DOR) N/A
Various
Davids et al. [58] Phase I 32 (8 MCL) ABT-199 100 (0) N/A N/A
aData derived from the overall population of the study, not exclusively from patients with MCL. Six patients received the schema as first-line therapy.
bFifteen patients received the antibody as relapse monotherapy, 30 patients as consolidation after salvage treatment.
mTOR, mammalian target of rapamycin; BCR, B-cell receptor; ORR, overall response rate; CR, complete response; PFS, progression-free survival; OS,
overall survival; TTP, time to progression; NR, not reached; TTF, time to failure; EFS, event-free survival; DOR, duration of response.
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the benefit seems to be minor in this setting [60], and there is
no role for a second autograft at relapse.
In younger patients, allogeneic stem-cell transplantation is
potentially curative and has achieved long-term remissions,
even in patients following early relapse and with refractory
disease. Based on the advanced age of most patients, a dose-
reduced conditioning is appropriate [IV, B] [61]. Haplo-identi-
cal bone marrow transplantation achieves high response rates
but is still experimental in MCL.
response evaluation
Radiological tests should be carried out mid-treatment and fol-
lowing the completion of chemotherapy. Patients who achieve
less than a PR should be considered for early salvage regimens.
Patients achieving a PR may convert to a complete response
after post-induction treatment.
PET-CT for response evaluation is optional [62].
The independent prognostic role of minimal residual disease
(MRD) applying patient-specific primers has been confirmed in nu-
merous studies [63, 64]. However, because of limitations of applic-
ability and the need for qualified and standardised laboratories, its
use is advised in clinical trials but not recommended in clinical
routine except the setting of donor lymphocyte infusion post allo-
graft.
Table 8. Summary of recommendations
Diagnostic procedures include histomorphology by an expert
haematopathologist and mandatory detection of cyclin D1
overexpression or t(11;14)(q13;q32)
Clinical (MIPI) and biological (Ki-67) prognosticators should be
applied in clinical routine to estimate the clinical behaviour
In localised stages: discuss conventional chemotherapy followed
by radiotherapy (30–36 Gy)
In advanced stages
Younger patients: high-dose cytarabine-containing regimens plus
rituximab with dose intensification (e.g. autologous stem-cell
transplantation)
Elderly patients: conventional immunochemotherapy (R-CHOP,
R-B) followed by rituximab maintenance
In relapse
(Combined) targeted approaches (bortezomib, ibrutinib,
temsirolimus, lenalidomide) should be considered
In younger patients, an allogeneic transplantation should be
discussed among possible options
Table 9. Levels of evidence and grades of recommendation
(adapted from the Infectious Diseases Society of America-United
States Public Health Service Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial
of good methodological quality (low potential for bias) or
meta-analyses of well-conducted randomised trials
without heterogeneity
II Small randomised trials or large randomised trials with
a suspicion of bias (lower methodological quality) or
meta-analyses of such trials or of trials with demonstrated
heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts
opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical
benefit, strongly recommended
B Strong or moderate evidence for efficacy but with a limited
clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not
outweigh the risk or the disadvantages (adverse events,
costs,… ), optional
D Moderate evidence against efficacy or for adverse outcome,
generally not recommended
E Strong evidence against efficacy or for adverse outcome,
never recommended
aBy permission of the Infectious Diseases Society of America [65].
Table 7. Recommended follow-up
Examination Details Year 1–2 Year 3–5 Year >5
History B symptoms Every 3 months Twice annually Annually
Physical
examination
Particular: peripheral lymph nodes, liver,
spleen
Every 3 months Twice annually Annually
Laboratory work-up Blood and differential count Every 3 months Twice annually Annually
LDH Every 3 months Twice annually Annually
Imaging Abdominal ultrasound Optional: 3–6 months Optional: every 6–12
months
If progress
suspected
CT neck, chest, abdomen, pelvis Optional: every 3–6
months
Optional: every 6–12
months
If progress
suspected
Toxicity TSH if irradiated Annually Annually Annually
LDH, lactate dehydrogenase; CT, computed tomography; TSH, thyroid-stimulating hormone.
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personalisedmedicine
In this disease setting, more research is needed to identify mo-
lecular markers which could lead to advances in personalised
medicine.
The selection of optimal treatment is mainly based on clinical
and biological risk factors, symptoms and tumour load (Figure 2).
PET- and MRD-based tailored treatments are currently evaluated
in studies but are not yet routine clinical practice.
New agents (especially inhibitors of Bruton’s tyrosine kinase
as well as PI3 kinases and BCL-2) are currently being investi-
gated [42].
follow-up and long-term implications
The following recommendations are based on consensus rather
than on evidence (see Table 7):
• History and physical examination, blood counts and routine
chemistry every 3 months for 2 years, every 4–6 months for 3
additional years and subsequently once a year [V, D].
• Annual evaluation of thyroid function in patients with irradi-
ation of the neck.
• Optional CT scan (or chest X-ray/ultrasound examinations
to reduce radiation exposure) every 3–6 months for 2 years
and every 6–12 months up to 5 years. However, there is no
strong evidence to support a regular radiological follow-up.
PET-CT should not be used for surveillance. These recom-
mendations are driven by the concern to minimise radiation
exposure.
• Some studies suggest that pre-emptive treatment may be effi-
cient. However, MRD screening may be carried out but
should not guide therapeutic strategies outside clinical studies.
note
A summary of recommended treatment strategies outside clinic-
al studies is provided in Figure 2, and a summary of recommen-
dations is provided in Table 8. Levels of evidence and grades of
recommendation have been applied using the system shown in
Table 9. Statements without grading were considered justified
standard clinical practice by the experts and the ESMO faculty.
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